文献速递临床免疫质量管理与危急值

脑脊液Aβ1-42检测准确性:新型Elecsys免疫分析前分析因素评估

Accuracy of cerebrospinal fluid Aβ1-42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunosassay.
PubMed 文献 · Clin Chem Lab Med · 2017-01-01

该研究评估了脑脊液Aβ1-42检测中多种前分析因素对测量准确性的影响,使用新型Elecsys免疫分析定量。结果显示低分子量Aβ寡聚化抑制剂、β-折叠破坏肽或4G8抗体不能改善反复冻融稳定性;冷冻保护剂仅在终浓度≥300 mM时减少冻融损失;Tween预处理或硅化管可防止Aβ1-42粘附。结论是仅通过标准化采集到特定管中、不离心不转移直接检测才能减少中心间变异。

要点

  • 低分子量Aβ寡聚化抑制剂、β-折叠破坏肽或4G8抗体不能改善脑脊液Aβ1-42反复冻融稳定性。
  • 冷冻保护剂仅在终浓度≥300 mM时减少冻融依赖的Aβ1-42损失。
  • Tween预处理或硅化管可防止Aβ1-42粘附,标准化采集直接检测可减少中心间变异。

核心结论

  • 仅通过标准化采集到特定管中、不离心不转移直接检测,才能减少脑脊液Aβ1-42测量的中心间变异。

研究设计与样本

  • 使用新型Elecsys免疫分析定量人脑脊液Aβ1-42浓度,评估多种前分析处理对反复冻融和粘附相关损失的影响。

主要发现

  • 低分子量Aβ寡聚化抑制剂、β-折叠破坏肽或mid domain 4G8抗体不改善反复冻融处理中脑脊液Aβ1-42的稳定性。
  • 冷冻保护剂仅在加入脑脊液至终浓度300 mM或更高时减少冻融依赖的Aβ1-42损失。
  • 用Tween预处理脑脊液或使用硅化表面管可防止Aβ1-42粘附。

关键数值与推荐

  • 冷冻保护剂终浓度需≥300 mM才减少冻融依赖的Aβ1-42损失。
  • 标准化采集到特定管中、不离心不转移直接检测可减少中心间变异。

临床怎么用

  • 脑脊液Aβ1-42检测应标准化采集到特定管中,不离心不转移直接检测,以减少中心间变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A decreased level of Aβ1-42 in cerebrospinal fluid (CSF) is characteristic of Alzheimer disease and often used to support clinical diagnosis. The measured concentration of CSF Aβ1-42, however, depends strongly on several pre-analytical and analytical "confounding" factors such as sample collection, material of testing tube, CSF handling and storage procedures (e.g. transfer to new tubes after centrifugation, freeze-thaw effects). As a consequence, substantial variations in the measured levels of this biomarker are observed even for the same sample. This study investigates whether the accuracy of quantitative analysis of CSF Aβ1-42 can be improved by pre-analytical treatment of CSF with agents that could potentially reduce a freeze-thaw and adhesion-related depletion of Aβ1-42 from CSF, including modulators of Aβ aggregation and cryoprotecting or anti-adhesion agents. METHODS: The concentration of CSF Aβ1-42 was assessed with a novel Elecsys immunoassay developed for quantification of Aβ1-42 in human CSF. RESULTS: Low-molecular weight Aβ oligomerization inhibitors, β-sheet breaker peptides, or the mid domain 4G8 antibody do not improve the stability of CSF Aβ1-42 during a repeated freeze-thaw treatment. Cryoprotecting agents reduce a freeze-thaw dependent loss of Aβ1-42 only when spiked to CSF to final concentration of 300 mM or higher. Adhesion of Aβ1-42 can be prevented by pre-treating CSF with Tween or by using tubes with a siliconized surface. CONCLUSIONS: Between-center variability in measured level of CSF Aβ1-42 can be reduced only by standardized CSF collection into one specific tube that, without centrifugation, transfer or other types of pre-analytical processing, is directly analyzed after sample collection.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Rozga M, Bittner T, Höglund K, et al. Accuracy of cerebrospinal fluid Aβ1-42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunosassay. Clin Chem Lab Med. 2017. PMID: 28160541. doi:10.1515/cclm-2016-1061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。